GenScript embraces automation at its first cell, gene therapy manufacturing US site

URLhttps://www.fiercepharma.com/manufacturing/genscri
SourceFierce Pharma
Date Published11/02/2021
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name GenScript
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Total number of jobs (added or to be added):200
Year reshoring announced:2021
Year reshoring implemented or to be implemented:2023
Domestically, the work will be done:In-house
Capital investment ($):13
Country(ies) from which reshored:China
City reshored to:Piscataway
State(s) reshored to:NJ
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredcell and gene therapies
What non-domestic negative factors made offshoring less attractive?Supply chain interruption risk/Natural disaster risk/Political instability
What domestic positive factors made reshoring more attractive?Automation/technology
Find Reshoring Articles